SCALP COOLING SYSTEM MARKET ANALYSIS

Scalp Cooling System Market, by Therapeutic Application (Chemotherapy Induced Hair loss, Neonatal Encephalopathy, and Cardiac Arrest), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI3294
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Global Scalp Cooling System Market – Regional Insights

North America accounted for the largest market share in 2018, owing to launches and approvals of new scalp cooling systems in the region. For instance, in June, 2019, the U.S. Food and Drug Administration (FDA) approved a new scalp cooling device DigniCap Delta developed by Dignitana Inc., to prevent chemotherapy-induced hair loss in patients with solid tumors. Similarly, in June 2018, the U.S Food and Drug Administration (FDA) approved Paxman advanced scalp cooling system developed by Paxman to reduce hair loss due to chemotherapy used in treating cancers such as breast, colorectal, bowel, ovarian, and prostate cancer. Furthermore, in May 2019, the company announced that it installed or signed delivery agreements for over 500 scalp cooling systems in the U.S to prevent chemotherapy induced hair loss.

Key players operating in the market include Dignitana Inc., Penguin Cold Caps, and Paxman.